CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer.

The Francis Crick Institute 2026 Dataset Open access

Read full text
Authors: Nourdine Kabirou Bah
DOI: 10.25418/crick.30988024.v1
Cited by: 0

Abstract

Datasets associated with CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Boumelha, J., de Castro, A., Bah, N., Cha, H., de Carné Trécesson, S., Rana, S., ... & Downward, J. (2024). CRISPR–Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer research, 84(14), 2231-2246.

Publication details

Journal / source
The Francis Crick Institute
Publication date
1 January 2026
Document type
Dataset